Potential drug-drug interactions at a referral hematology-oncology ward in Iran: A cross-sectional study

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 6, 2013, Pages 1619-1627

  Hadjibabaie, Molouk ^a   Badri, Shirinsadat ^b   Ataei, Sarah ^a   Moslehi, Amir Hossein ^a   Karimzadeh, Iman ^a   Ghavamzadeh, Ardeshir ^c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug drug interactions; Hematological malignancies; Hematology oncology ward; Iran

Indexed keywords

ALLOPURINOL; ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; ATORVASTATIN; CORTICOSTEROID DERIVATIVE; COTRIMOXAZOLE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLUCONAZOLE; GANCICLOVIR; GRANISETRON; IMATINIB; IMIPENEM; METHYLPREDNISOLONE; MITOXANTRONE; PHENYTOIN; VANCOMYCIN; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; CANDIDIASIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; IRAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PRIORITY JOURNAL; QT PROLONGATION; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; DRUG INTERACTIONS; DRUG TOXICITY; FEMALE; HEMATOLOGIC NEOPLASMS; HOSPITAL DEPARTMENTS; HOSPITALS, UNIVERSITY; HUMANS; IRAN; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ONCOLOGY SERVICE, HOSPITAL; PHARMACEUTICAL PREPARATIONS; YOUNG ADULT;

EID: 84878645718     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2162-5     Document Type: Article

References (45)

1. Fuhr U (2008) Improvement in the handling of drug-drug interactions. Eur J Clin Pharmacol 64:167-171
2. Scripture CD, Figg WD (2006) Drug interactions in cancer therapy. Nat Rev Cancer 6:546-558
3. Lu C, Liao M, Cohen L, Xia CQ (2010) Emerging in vitro tools to evaluate cytochrome P450 and transporter-mediated drug-drug interactions. Curr Drug Discov Technol 7:199-222
4. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH (2000) Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 38:504-513
5. Beijnen JH, Schellens JH (2004) Drug interactions in oncology. Lancet Oncol 5:489-496
6. Egger SS, Drewe J, Schlienger RG (2003) Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol 58:773-778
7. Glintborg B, Andersen SE, Dalhoff K (2005) Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 61:675-681
8. Herr RD, Caravati EM, Tyler LS, Iorg E, Linscott MS (1992) Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med 21:1331-1336
9. Goldberg RM, Mabee J, Chan L, Wong S (1996) Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med 14:447-450
10. Guédon-Moreau L, Ducrocq D, Duc MF, Quieureux Y, L'Hôte C, Deligne J, Caron J (2004) Absolute contraindications in relation to potential drug interactions in outpatient prescriptions: analysis of the first five million prescriptions in 1999. Eur J Clin Pharmacol 59:899-904
11. Buajordet I, Ebbesen J, Erikssen J, Brørs O, Hilberg T (2001) Fatal adverse drug events: the paradox of drug treatment. J Intern Med 250:327-341
12. Riechelmann RP, Del Giglio A (2009) Drug interactions in oncology: how common are they? Ann Oncol 20:1907-1912
13. Lexi-interact. http://webstore.lexi.com/Lexi-Interact. Accessed June 1 2012
14. Barrons R (2004) Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm 61:380-385
15. Vonbach P, Dubied A, Krähenbühl S, Beer JH (2008) Evaluation of frequently used drug interaction screening programs. Pharm World Sci 30:367-374
16. Reis AM, Cassiani SH (2010) Evaluation of three brands of drug interaction software for use in intensive care units. Pharm World Sci 32:822-828
17. World Health Organization. Collaborating Center for Drug Statistics Methodology. ATC/DDD Index 2012. http://www.whocc.no/atcddd/index. Accessed 1 June 2012
18. Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK (2007) Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst 99:592-600
19. Kannan G, Anitha R, Rani VN, Thennarasu P, Alosh J, Vasantha J, Martin JR, Uma MR (2011) A study of drug-drug interactions in cancer patients of a south Indian tertiary care teaching hospital. J Postgrad Med 57:206-210
20. Guastaldi RB, Reis AM, Figueras A, Secoli SR (2011) Prevalence of potential drug-drug interactions in bone marrow transplant patients. Int J Clin Pharm 33:1002-1009
21. Riechelmann RP, Moreira F, Smaletz O, Saad ED (2005) Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol 56:286-290
22. Strandell J, Wahlin S (2011) Pharmacodynamic and pharmacokinetic drug interactions reported to VigiBase, the WHO global individual case safety report database. Eur J Clin Pharmacol 67:633-641
23. McCoy D, Depestel DD, Carver PL (2009) Primary antifungal prophylaxis in adult hematopoietic stem cell transplant recipients: current therapeutic concepts. Pharmacotherapy 29:1306-1325
24. Nivoix Y, Ubeaud-Sequier G, Engel P, Levêque D, Herbrecht R (2009) Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care. Curr Drug Metab 10:395-409
25. Cronin S, Chandrasekar PH (2010) Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 65:410-416
26. Leather HL (2004) Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant 33:137-152
27. Schmidt H, Naumann R, Jaschonek K, Einsele H, Dopfer R, Ehninger G (1989) Drug interaction between cyclosporin and phenytoin in allogeneic bone marrow transplantation. Bone Marrow Transplant 4:212-213
28. Keown PA, Laupacis A, Carruthers G, Stawecki M, Koegler J, McKenzie FN, Wall W, Stiller CR (1984) Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 38:304-306
29. Freeman DJ, Laupacis A, Keown PA, Stiller CR, Carruthers SG (1984) Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporin metabolites. Br J Clin Pharmacol 18:887-893
30. Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S (2009) Drug interaction between voriconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 44:371-374
31. van der Ven AJ, Schoondermark-van de Ven EM, Camps W, Melchers WJ, Koopmans PP, van der Meer JW, Galama JM (1996) Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J Antimicrob Chemother 38:75-80
32. Gill HJ, Maggs JL, Madden S, Pirmohamed M, Park BK (1996) The effect of fluconazole and ketoconazole on the metabolism of sulphamethoxazole. Br J Clin Pharmacol 42:347-353
33. Winter HR, Trapnell CB, Slattery JT, Jacobson M, Greenspan DL, Hooton TM, Unadkat JD (2004) The effect of clarithromycin, fluconazole, and rifabutin on sulfamethoxazole hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283). Clin Pharmacol Ther 76:313-322
34. Au WY, Kwong YL (2008) Arsenic trioxide: safety issues and their management. Acta Pharmacol Sin 29:296-304
35. Bagnes C, Panchuk PN, Recondo G (2010) Antineoplastic chemotherapy induced QTc prolongation. Curr Drug Saf 5:93-96
36. Lien YC, Lin SM, Nithipongvanitch R, Oberley TD, Noel T, Zhao Q, Daosukho C, St Clair DK (2006) Tumor necrosis factor receptor deficiency exacerbated Adriamycin-induced cardiomyocytes apoptosis: an insight into the Fas connection. Mol Cancer Ther 5:261-269
37. Hilmer SN, Cogger VC, Muller M, Le Couteur DG (2004) The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab Dispos 32:794-799
38. Barbui T, Rambaldi A, Parenzan L, Zucchelli M, Perico N, Remuzzi G (1992) Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet 339:1421
39. Rushing DA, Raber SR, Rodvold KA, Piscitelli SC, Plank GS, Tewksbury DA (1994) The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 74:834-841
40. Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P (1993) Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin. Cancer Res 53:4837-4842
41. Sonneveld P, Suciu S, Weijermans P, Beksac M, Neuwirtova R, Solbu G, Lokhorst H, van der Lelie J, Dohner H, Gerhartz H, Segeren CM, Willemze R, Lowenberg B, European Organization for Research and Treatment of Cancer (EORTC), Leukaemia Cooperative Group (LCG), Dutch Haemato-Oncology Cooperative Study Group (HOVON) (2001) Cyclosporin A combined with vincristine, doxorubicin and dexamethasone (VAD) compared with VAD alone in patients with advanced refractory multiple myeloma: an EORTC-HOVON randomized phase III study (06914). Br J Haematol 115:895-902
42. Bartlett NL, Lum BL, Fisher GA, Brophy NA, Ehsan MN, Halsey J, Sikic BI (1994) Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol 12:835-842
43. Riechelmann RP, Zimmermann C, Chin SN, Wang L, O'Carroll A, Zarinehbaf S, Krzyzanowska MK (2008) Potential drug interactions in cancer patients receiving supportive care exclusively. J Pain Symptom Manage 35:535-543
44. Secoli SR, Figueras A, Lebrão ML, de Lima FD, Santos JL (2010) Risk of potential drug-drug interactions among Brazilian elderly: a population-based, cross-sectional study. Drugs Aging 27:759-770
45. Miranda V, Fede A, Nobuo M, Ayres V, Giglio A, Miranda M, Riechelmann RP (2011) Adverse drug reactions and drug interactions as causes of hospital admission in oncology. J Pain Symptom Manage 42:342-353